Donidalorsen

antisense oligonucleotide targeting prekallikrein · Ionis Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Donidalorsen, covering 2022-09-28 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Donidalorsen Treatment in Children With Hereditary Angioedema [Phase 3]